Education
About Us
Working with TipRanks
Follow Us
RegenXBio (RGNX)
NASDAQ:RGNX
RGNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.04 - $17.52
Previous CloseN/A
Volume155.59K
Average Volume (3M)1.01M
Market Cap
$492.65M
Enterprise Value$290.05M
Total Cash (Recent Filing)$1.12M
Total Debt (Recent Filing)$2.40M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Jul 30, 2025EPS Estimate
0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.64
Shares Outstanding50,116,910
10 Day Avg. Volume904,308
30 Day Avg. Volume1,013,084
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.83
Enterprise Value/Ebitda-1.46
Forecast
1Y Price Target
$32.50Price Target Upside212.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Competitive DifferentiationThe use of a different AAV capsid (AAV8) and transgene by RGNX compared to Elevidys differentiates RGNX's approach from competitors.
Efficacy And SafetyRGX-202 demonstrates favorable safety profile with no serious adverse events and no adverse events of special interest.
Regulatory ProspectsRGX-202's successful elicitation of robust microdystrophin expression across all age groups well above the threshold for regulatory approval bodes well for the trial's readout and potential approval.
Bears Say
Commercial ImpactA recent DMD patient death after being treated with Elevidys could temper physician enthusiasm for the class in the near-term.
Market PerceptionSafety will be closely scrutinized following a patient death from acute liver failure linked to a competitor's treatment, highlighting the need for ongoing monitoring.
---
Ownership Overview
8.70% Insiders
13.91% Mutual Funds
1.51% Other Institutional Investors
64.25% Public Companies and
Individual Investors
RGNX FAQ
What was RegenXBio’s price range in the past 12 months?
RegenXBio lowest stock price was $5.04 and its highest was $17.52 in the past 12 months.
What is RegenXBio’s market cap?
RegenXBio’s market cap is $492.65M.
When is RegenXBio’s upcoming earnings report date?
RegenXBio’s upcoming earnings report date is Jul 30, 2025 which is in 88 days.
How were RegenXBio’s earnings last quarter?
Currently, no data Available
Is RegenXBio overvalued?
According to Wall Street analysts RegenXBio’s price is currently Undervalued.
Does RegenXBio pay dividends?
RegenXBio does not currently pay dividends.
What is RegenXBio’s EPS estimate?
RegenXBio’s EPS estimate is 0.46.
How many shares outstanding does RegenXBio have?
RegenXBio has 50,116,910 shares outstanding.
What happened to RegenXBio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of RegenXBio?
Currently, no hedge funds are holding shares in RGNX
---
RegenXBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.50 (212.50% Upside)
$32.50 (212.50% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 11.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.1%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.32%
12-Months-Change
Fundamentals
Return on Equity
-79.49%
Trailing 12-Months
Asset Growth
-18.81%
Trailing 12-Months
Company Description
RegenXBio
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
---
RGNX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a largely positive outlook with significant advancements in multiple programs, strong partnerships, and a solid financial position. The highlights of new BLA submissions, expected FDA approvals, and strategic partnerships significantly outweigh the lowlights, which include a decrease in cash and R&D expenses.Read More>---
RGNX Stock 12 Month Forecast
Average Price Target
$32.50
▲(212.50% Upside)
Technical Analysis
Inventiva
―
Taysha Gene Therapies
―
Verve Therapeutics
―
Erasca
―
Amylyx Pharmaceuticals Inc
―
---